| Literature DB >> 26979771 |
Sapna Aggarwal1, Puneet Kaur Randhawa1, Nirmal Singh1, Amteshwar Singh Jaggi2.
Abstract
There is growing preclinical as well as clinical evidence supporting remote ischemic preconditioning (RIPC), in which short cycles of non-fatal ischemia followed by reperfusion to an organ or tissue distant from the heart elicits cardioprotection. It is the most practical, non-invasive, cost-free, and clinically compatible, secure procedure for reducing ischemia-reperfusion induced injury. The use of a conventional blood pressure cuff on the upper or lower limb in eliciting cardioprotection has expedited its clinical applicability. Endothelium has been documented to respond very quickly to blood flow and hypoxia by releasing different humoral factors such as endothelium derived releasing factor, endothelium derived contracting factor, endothelium derived hyperpolarizing factor. In recent years, there have been studies suggesting the key role of endothelial derived factors in RIPC induced cardioprotection. The signaling cascade involves nitric oxide, gap junctions, epoxyeicosatrienoic (EETs) acids, Ca-activated K(+) channels, angiotensin II, thromboxane A2, superoxide anions and prostacyclin. The present review describes the role of these endothelial derived factors in RIPC induced cardioprotection with possible mechanisms.Entities:
Keywords: Cardioprotection; Endothelium; Endothelium derived factor; Ischemia-reperfusion injury; Nitric oxide; Remote ischemic preconditioning
Mesh:
Substances:
Year: 2016 PMID: 26979771 DOI: 10.1016/j.lfs.2016.03.021
Source DB: PubMed Journal: Life Sci ISSN: 0024-3205 Impact factor: 5.037